Diagnostic imaging, sepsis prediction, ambient clinical documentation, prior authorisation, drug discovery and patient-facing chatbots now operate under the densest overlap of device law, data law, AI statutes and accreditation standards of any industry, and the bodies behind all four changed their expectations materially across 2025 and 2026. AxiLayer AI and AxiSentinel™ give health systems, payers, device and SaMD makers, pharma and health-AI vendors in the UAE and GCC, the European Union, Asia-Pacific, the UK and North America continuous, independent evidence that every model touching a patient is still safe, fair and within its approved envelope.
Across late 2025 and 2026, healthcare regulators, legislatures and accreditors converged on the same demand from different directions: not proof that an algorithm was validated once, but proof that someone is watching it now that it is treating patients.
The FDA has authorised 1,451 AI-enabled devices, overwhelmingly via the 510(k) pathway on retrospective and often single-site data, and its lifecycle-management guidance for AI devices, drafted in January 2025, remains unfinalised. Meanwhile most clinical AI, EHR-embedded deterioration scores, ambient scribes, generative assistants, never passes through device review at all. Performance at your site, on your population, after the vendor’s next update is nobody’s approval and everybody’s liability. That is a monitoring problem, not a documentation problem.
Health-AI vendors preparing for procurement and health-system due diligence are covered in depth on the dedicated vendor assessment page.
Go to Vendor AssessmentsA single deterioration model or triage chatbot deployed across a multinational provider group can simultaneously be an FDA-regulated device function in the US, an Annex I high-risk system under the EU AI Act, a high-impact system under Korea’s AI Framework Act, and subject to the DoH Abu Dhabi AI policy, while the data feeding it answers to HIPAA, GDPR, the EHDS and Gulf residency rules. Each regime wants different evidence in a different format. This is the coverage map.
The Gulf pairs the region’s earliest health-AI rulebook with the world’s densest live deployment surface, emirate-scale health information exchanges running AI across entire populations.
US health AI answers to a device regulator, a privacy enforcer, an EHR certification programme, fifty legislatures and an accreditor, and in 2025 to 26 all five moved.
Medical AI in Europe is a dual-conformity problem: the same system must satisfy the MDR or IVDR and the AI Act, assessed by notified bodies that are already the system’s scarcest resource.
Beneath the UK’s sandbox headlines sits the older statute that actually gates market entry: the Medical Devices Regulations 2002, still the operative law for Great Britain now that Northern Ireland instead follows the EU regime.
Three regulators reforming device law for AI without an AI act: sandbox-driven in the UK, guidance-led in Canada, framework-review-led in Australia.
Asia-Pacific holds both the strictest binding classification of health AI (Korea) and the most operationally specific lifecycle guidance (Singapore), with the region’s largest device markets accelerating approvals underneath.
No treaty governs health AI, but a recognisable global baseline now exists, and every national regulator on this page cites some part of it.
Each use case below carries a specific classification, a specific evidence expectation and a specific supervisor, or accreditor, in each market. AxiSentinel is configured per use case and per jurisdiction rather than shipped as one fixed pipeline.
AxiSentinel does not replace clinical governance, quality committees or regulatory affairs. It gives all three a continuous, independent evidence feed, and it gives the board something it currently cannot get, which is an answer to “is every model touching a patient still performing, here, today?”
The first ask of the Joint Commission, CHAI, AIHGle 2.0 and Korea’s Act alike, maintained continuously from what is actually running, including EHR-embedded models switched on by default.
Continuous local validation evidence per deployment site and per population, the answer to models approved on someone else’s data, and the practical watch on the EU’s undefined “substantial modification” threshold.
Ongoing, evidenced testing across demographic groups, age, sex, ethnicity, payer class and site, sized for CHAI expectations, EU fairness duties and the risk-score failure modes the literature documents.
Evidence that HTI-1’s 31 source attributes, Korea’s explanation duties and Article 50 disclosures are present, accurate and current, not merely that they were written once.
Detects alert fatigue, override anomalies and rubber-stamped physician review, the specific failure SB 1120 legislates against and every clinician-in-the-loop regime assumes away.
Evidence that every model update stayed inside its predetermined change control plan, FDA’s final guidance of December 2024, the UK’s draft 2026 equivalent and Korea’s pre-approved change plans.
Incident, trend and performance records shaped for MDR/IVDR post-market surveillance, the GB PMS regulations and the FDA’s lifecycle expectations, generated continuously, not reconstructed at audit.
The AXI-Node agent runs inside your own environment, cloud, on-premise or fully air-gapped via the .axibatch format, so HIPAA, GDPR, EHDS and Gulf health-data residency are satisfied by architecture, not by exception.
Hallucination and omission detection for scribes and clinical copilots, disclaimer compliance under AB 3030, and the device-boundary evidence MHRA’s ambient voice guidance now expects.
Most hospital AI is bought, not built, and every regime on this page makes the deployer accountable anyway. Vendor and foundation-model behaviour is monitored in situ, in your environment.
Tamper-evident, time-ordered records for accreditation surveys, notified bodies, FDA inspections and internal quality committees, verifiable independently of AxiLayer AI.
Evidence that deactivation and rollback mechanisms exist, are tested and have been exercised, the last line of defence when a clinical model drifts, and the first question after an incident.
Hospitals do not run model risk functions the way banks do, they run quality, safety and accreditation programmes with mature budgets and board committees. The Joint Commission and CHAI just routed AI governance directly into that machinery, device regulators attached dated post-market duties to 1,451 authorised products, and state legislatures made the deployer personally answerable. The buyer does not need persuading that patient safety matters; they need evidence infrastructure their EHR vendor cannot independently provide.
A clinical AI estate review maps every model touching patients or claims, bought or built, device or not, against each regulator, statute and accreditor that supervises it: classification, evidence expectation, deadline and gap, and what continuous monitoring would look like inside your own environment, including fully air-gapped.
